tetranor-PGDM – 100 µg

Brand:
Cayman
CAS:
70803-91-7
Storage:
-80
UN-No:
De Minimis - 1230 / 3|6.1

Prostaglandin D2 (PGD2; Item No. 12010) is synthesized by hematopoietic-type PGD-synthase (H-PGDS) in mast cells and is released in large quantities during allergic and asthmatic anaphylaxis.{416} PGD2 is also produced in the brain by lipocalin-PGD-synthase also known as β-trace.{328,1185} In the brain, PGD2 produces normal physiological sleep and lowering of body temperature.{328,1185} Further pharmacological actions include inhibition of platelet aggregation and relaxation of vascular smooth muscle.{580} tetranor-PGDM is a major metabolite of PGD2 that is detectable in human and mouse urine.{15162} The levels of tetranor-PGDM and 2,3-dinor-11β-PGF2α (Item No. 16530), a related PGD2 metabolite, in human urine were found to be 1.5 ± 0.3 and 0.6 ± ng/mg creatinine, respectively. tetranor-PGDM was detected in murine urine at a level of 8.1 ± 1.3 ng/mg creatinine.{15162}  

 

Available on backorder

SKU: 12850 - 100 µg Category:

Description

A major metabolite of PGD2 found in human and mouse urine at levels of approximately 1.5 and 8.1 ng/mg creatinine, respectively


Formal name: 9α-hydroxy-11,15-dioxo-13,14-dihydro-2,3,4,5-tetranor-prostan-1,20-dioic acid

Synonyms:  tetranor-PGD Metabolite|tetranor-Prosatglandin D Metabolite

Molecular weight: 328.4

CAS: 70803-91-7

Purity: ≥90%

Formulation: A solution in methanol


Product Type|Biochemicals|Lipids|Prostaglandins||Research Area|Immunology & Inflammation||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway